| [1] |
Lu Q,Davel AP,Mcgraw AP,et al.PKCδ mediates mineralocorticoid receptor activation by angiotensin ii to modulate smooth muscle cell function[J].Endocrinology,2019,160:2101-2114.
|
| [2] |
Ong GSY,Young MJ.Mineralocorticoid regulation of cell function:the role of rapid signalling and gene transcrip-tion pathways[J].J Mol Endocrinol,2017,58:33-57.
|
| [3] |
González-Blázquez R,Somoza B,Gil-Ortega M,et al.Finerenone atenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress[J].Front Pharmacol,2018,9:1131-1144.
|
| [4] |
Shen JZ,Morgan J,Tesch GH,et al.Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages[J].Endocrinology,2016,157:3213-3223.
|
| [5] |
Moss ME,Lu Q,Iyer SL,et al.Endothelial mineralocor-ticoid receptors contribute to vascular inflammation in atherosclerosis in a sex-specific manner[J].Arterioscler Thromb Vasc Biol,2019,39:1588-1601.
|
| [6] |
Ferreira NS,Bruder-Nascimento T,Pereira CA,et al.NLRP3 inflammasome and mineralocorticoid receptors are associated with vascular dysfunction in type 2 diabetes mellitus[J].Cells,2019,8:1595-1608.
|
| [7] |
Zheng XJ,Liu Y,Zhang WC,et al.Mineralocorticoid receptor negatively regulates angiogenesis through repres-sion of STAT3 activity in endothelial cells[J].J Pathol,2019,248:438-451.
|
| [8] |
Kim SK,Mccurley AT,Dupont JJ,et al.Smooth muscle cell-mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging[J].Hypertension,2018,71:609-621.
|
| [9] |
Araos P,Prado C,Lozano M,et al.Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation[J].J Hypertens,2019,37:1482-1492.
|
| [10] |
Aroor AR,Habibi J,Nistala R,et al.Diet-induced obesity promotes kidney endothelial stiffening and fibrosis dependent on the endothelial mineralocorticoid receptor[J].Hypertension,2019,73:849-858.
|
| [11] |
Nakamura T,Kurihara I,Kobayashi S,et al.Intestinal mineralocorticoid receptor contributes to epithelial sodium channel-mediated intestinal sodium absorption and blood pressure regulation[J].J Am Heart Assoc,2018,7:e008259.doi:10.1161/JAHA.117.008259.
|
| [12] |
Ferreira JP,Rossignol P,Pizard A,et al.Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure[J].Heart,2019,105:307-314.
|
| [13] |
Ito S,Itoh H,Rakugi H,et al.Double-blind randomized phase 3 study comparing esaxerenone (cs-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)[J].Hypertension,2020,75:51-58.
|
| [14] |
Brown SM,Meuth AI,Davis JW,et al.Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction:a unique vascular transcriptomic signature[J].Pharmacol Res,2018,134:100-108.
|
| [15] |
Shen ZX,Chen XQ,Sun XN,et al.Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis[J].J Biol Chem,2017,292:925-935.
|
| [16] |
Fraccarollo D,Thomas S,Scholz CJ,et al.Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing[J].Hypertension,2019,73:102-111.
|
| [17] |
Kosmala W,Przewlocka-Kosmala M,Marwick TH.Association of active and passive components of lv diastolic filling with exercise intolerance in heart failure with preserved ejection fraction:mechanistic insights from spironolactone response[J].JACC Cardiovasc Imaging,2019,12:784-794.
|
| [18] |
Mcdiarmid AK,Swoboda PP,Erhayiem B,et al.Myocardial effects of aldosterone antagonism in heart failure with preserved ejection fraction[J].J Am Heart Assoc,2020,9:e011521.doi:10.1161/JAHA.118.011521.
|
| [19] |
Serenelli M,Jackson A,Dewan P,et al.Mineralocorti-coid receptor antagonists,blood pressure,and outcomes in heart failure with reduced ejection fraction[J].JACC Heart Fail,2020,8:188-198.
|
| [20] |
Bienvenu LA,Morgan J,Reichelt ME,et al.Chronic in vivo nitric oxide deficiency impairs cardiac functional recovery after ischemia in female (but not male) mice[J].J Mol Cell Cardiol,2017,112:8-15.
|
| [21] |
Driessen HE,Fontes MS,Van Stuijvenberg L,et al.A combined CaMKII inhibition and mineralocorticoid recep-tor antagonism via eplerenone inhibits functional deterioration in chronic pressure overloaded mice[J].J Cell Mol Med,2020,24:8417-8429.
|
| [22] |
Yi Y,Du L,Qin M,et al.Regulation of atrial fibrosis by the bone[J].Hypertension,2019,73:379-389.
|
| [23] |
Wang Y,Zhong B,Wu Q,et al.Aldosterone contributed to pulmonary arterial hypertension development via stimulating aquaporin expression and pulmonary arterial smooth muscle cells proliferation[J].Pharmacology,2020,105:405-415.
|
| [24] |
Boehm M,Arnold N,Braithwaite A,et al.Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension[J].BMC Pulm Med,2018,18:41-58.
|
| [25] |
Elinoff JM,Chen LY,Dougherty EJ,et al.Spironolac-tone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling[J].Cardiovasc Res,2018,114:65-76.
|
